Wall Street Analyst Initiated Sorrento Therapeutics Inc. [SRNE]. What else is Wall St. saying

Related

Sorrento Therapeutics Inc. [NASDAQ: SRNE] plunged by -$0.13 during the normal trading session on Monday and reaching a high of $2.67 during the day while it closed the day at $2.47. The company report on July 19, 2022 that Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


STI-1558, an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of COVID-19.

Studies to date indicate that STI-1558 does not require the co-administration of ritonavir as a booster for CYP3A4 inhibition.

Sorrento Therapeutics Inc. stock has also loss -3.89% of its value over the past 7 days. However, SRNE stock has inclined by 63.58% in the 3 months of the year. Over the past six months meanwhile, it has lost -16.55% and lost -46.88% year-on date.

The market cap for SRNE stock reached $975.45 million, with 337.12 million shares outstanding and 312.41 million shares in the current float. Compared to the average trading volume of 10.58M shares, SRNE reached a trading volume of 7122659 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Sorrento Therapeutics Inc. [SRNE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRNE shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.

The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.23, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 17.11. The Price to Book ratio for the last quarter was 3.69, with the Price to Cash per share for the same quarter was set at 0.69.

SRNE stock trade performance evaluation

Sorrento Therapeutics Inc. [SRNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.89. With this latest performance, SRNE shares gained by 22.89% in over the last four-week period, additionally sinking by -16.55% over the last 6 months – not to mention a drop of -69.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 51.13, with the RSI for the last a single of trading hit 45.65, and the three-weeks RSI is set at 53.31 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 2.09, while it was recorded at 2.57 for the last single week of trading, and 3.47 for the last 200 days.

Sorrento Therapeutics Inc. [SRNE]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -695.68 and a Gross Margin at +67.54. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -809.63.

Return on Equity for this stock declined to -351.23, with Return on Assets sitting at -62.45.

Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.

Earnings per share (EPS) analysis for Sorrento Therapeutics Inc. [SRNE] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.

Sorrento Therapeutics Inc. [SRNE]: Insider Ownership positions

There are presently around $318 million, or 35.30% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: STATE STREET CORP with ownership of 33,960,884, which is approximately 132.676% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 22,034,889 shares of the stock with an approximate value of $54.43 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $39.28 million in SRNE stock with ownership of nearly 1.33% of the company’s market capitalization.

Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 121 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 42,368,029 shares. Additionally, 75 investors decreased positions by around 6,369,509 shares, while 68 investors held positions by with 80,203,481 shares. The mentioned changes placed institutional holdings at 128,941,019 shares, according to the latest SEC report filing. SRNE stock had 39 new institutional investments in for a total of 5,833,057 shares, while 37 institutional investors sold positions of 3,526,786 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]